Skip to main content

Forbion Capital Partners — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

122
Companies
$9.1B
Total invested
$91.4M
Avg. check
15
Industries
Biotechnology 22Health Care 11Medical 9Therapeutics 8Life Science 5Pharmaceutical 5+9 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 122
Solasta Bio
September 2024

Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.

AgTech · Glasgow$14.0M Series A
Navigator Medicines
August 2024

Navigator Medicines operate as a biotech company.

Biotechnology · Scotch Plains$100.0M Series A
NeRRe Therapeutics
July 2021

NeRRe Therapeutics is a biotechnology company that develops clinical and pre-clinical neurokinin receptor antagonists.

Biotechnology · Stevenage$27.6M Series B
Dyne Therapeutics
July 2026

Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.

Biotechnology · Cambridge$375.1M Post-IPO Equity
Achilles Therapeutics
July 2022

Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.

Biotechnology · London$4.1M Grant
CatalYm
July 2024

CatalYm is a biotechnology company developing innovative immunotherapies for cancer patients.

Biotechnology · Planegg$150.0M Series D
Mosanna Therapeutics
June 2025

Mosanna Therapeutics develops a nasal spray for treating obstructive sleep apnea.

Biotechnology · Redwood City$80.0M Series A
RQ Bio
June 2026

RQ Bio is a biotechnology company that develops medicine based on potent broad-spectrum mAbs to provide immunity to viral infections.

Biotechnology · London$112.5M Series A
Memento Medicines
June 2026

Memento Medicines is a biotech developing bispecific antibody therapies for eye diseases.

Biotechnology · Chester$93.0M Series A
Marea Therapeutics
June 2024

Marea is a biotechnology company that develops therapies and medications for the treatment of cardioendocrine illness patients.

Biotechnology · San Francisco$190.0M Series B
Dualyx
May 2023

Dualyx engages in the discovery and development of biologicals for the treatment of autoimmune and rare diseases.

Biotechnology · Ghent$43.5M Series A
Seamless Therapeutics
April 2024

Seamless Therapeutics is reshaping the gene editing paradigm with a novel approach to restoring health in patients.

Genetics · Dresden$12.6M Seed
Complement Therapeutics
April 2023

Complement Therapeutics operates as a preclinical stage company.

Biotechnology · London$78.7M Series A
AIRNA
April 2025

AIRNA develops RNA editing technologies to create medicines for various diseases.

Biotechnology · Cambridge$155.0M Series B
Engrail Therapeutics
March 2024

Engrail Therapeutics is a developer of medicines to transform the lives of patients with life-limiting diseases of the nervous system.

Health Care · San Diego$167.0M Series B
Mestag Therapeutics
March 2026

Mestag Therapeutics is a biotechnology company that develops new therapies for diseases using fibroblast technology.

Biotechnology · Cambridge$40.0M Series Unknown
Precirix
March 2022

Precirix is a platform that is developing radio-immunotherapeutic drugs for cancer patients.

Biotechnology · Brussels$88.2M Series B
Tropic Biosciences
March 2026

Tropic Biosciences is a pioneering leader in the development of novel high-performing commercial tropical crop varieties and traits.

Agriculture · London$105.0M Series C
Genetix Biotherapeutics Inc.
February 2025

Genetix Biotherapeutics develops and delivers approved gene therapies for severe rare genetic diseases like sickle cell.

Biotechnology · SomervillePrivate Equity
Altesa
February 2026

Altesa is a clinical-stage biopharmaceutical company dedicated to accelerating the development of new treatments

Biotechnology · College Park$75.0M Series B
PACT
October 2025

PACT designs Elegant materials produced in tune with the planet earth.

Biotechnology · Cambridge$21.1M Series A
Elevara Medicine
October 2025

Elevara is a clinical-stage firm working on innovative therapies to treat rheumatoid arthritis and other chronic inflammatory disorders.

Biotechnology · London$70.0M Series A
Expedition Therapeutics
October 2025

Expedition Therapeutics is a biotechnology company that develops novel therapies for inflammatory and respiratory diseases.

Biotechnology · San Francisco$165.0M Series A
Sparrow Pharmaceuticals
September 2025

Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for disorders of corticosteroid excess.

Biopharma · Portland$95.0M Series B

Where Forbion Capital Partners invests

Biotechnology22
Health Care11
Medical9
Therapeutics8
Life Science5
Pharmaceutical5

About Forbion Capital Partners's portfolio

How many companies has Forbion Capital Partners invested in?

Forbion Capital Partners has invested in 122 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Forbion Capital Partners invest in?

Forbion Capital Partners's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Life Science. The firm invests across 15 different industry categories.

What is Forbion Capital Partners's largest investment?

Among tracked funding rounds, Dyne Therapeutics received $375.1M in a Post-IPO Equity round. Forbion Capital Partners's total known invested capital is $9.1B.

What is the average investment size for Forbion Capital Partners?

Forbion Capital Partners's average investment size is $91.4M across its portfolio of 122 companies.

What are Forbion Capital Partners's most recent investments?

Recent Forbion Capital Partners portfolio additions include Solasta Bio, Navigator Medicines, NeRRe Therapeutics, Dyne Therapeutics, Achilles Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 122 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →